Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification

Modern Pathology

Volumn 19, Issue 7, 2006, Pages 942-949

  Alvarez, Gustavo ^a   Perry, Arie ^a   Tan, Benjamin R ^a   Wang, Hanlin L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anal canal; EGFR; Fluorescence in situ hybridization; Gene amplification; Immunohistochemistry; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ANUS CARCINOMA; ARTICLE; DISOMY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINIZATION; MONOSOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; UP-REGULATION;

EID: 33745185990     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800608     Document Type: Article

References (47)

1. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-26.
2. Koretz K, Schlag P, Moller P. Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch A Pathol Anat Histopathol 1990;416:343-349.
3. Steele RJ, Kelly P, Ellul B, et al. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990;77:1352-1354.
4. Yasui W, Sumiyoshi H, Hata J, et al. Expression of epidermal growth factor in human gastric and colonic carcinomas. Cancer Res 1988;48:137-141.
5. Pfeiffer A, Rothbauer E, Wiebecke B, et al. Increased epidermal growth factor receptors in gastric carcinomas. Gastroenterology 1990;98:961-967.
6. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth, factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74:795-804.
7. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal Growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41:S29-S42.
8. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-522.
9. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-2616.
10. Sainsbury JR, Farndon JR, Sherbet GV, et al. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1985;1:364-366.
11. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1:366-368.
12. Sargent ER, Gomella LG, Belldegrun A, et al. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 1989;142:1364-1368.
13. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003;25:67-73.
14. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;313:745-747.
15. Calvo E, Rowinsky EK. Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr Oncol Rep 2005;7:96-103.
16. Kopp R, Rothbauer E, Mueller E, et al. Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Dis Colon Rectum 2003;46:1391-1399.
17. El-Rayes BF, LoRusso PM. Targeting the epidermal growth factor receptor. Br J Cancer 2004;91:418-424.
18. Hinoda Y, Sasaki S, Ishida T, et al. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 2004;95:621-625.
19. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
20. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
21. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654.
22. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004;40:1292-1301.
23. Burtness B. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck. J Clin Oncol 2005;23:5440-5442.
24. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
25. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
26. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-487.
27. Frisch M. On the etiology of anal squamous carcinoma. Dan Med Bull 2002;49:194-209.
28. Licitra L, Spinazzé S, Doci R, et al. Cancer of the anal region. Crit Rev Oncol Hematol 2002;43:77-92.
29. Lu DW, El-Mofty SK, Wang HL. Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA. Mod Pathol 2003;16:692-699.
30. Wang HL. Role of immunohistochemical expression of p53, Rb, and p16 proteins in anal squamous cell carcinoma. In: Hayat MA (ed). Handbook of Immunohistochemistry and In Situ Hybridization of Human Carcinomas. Volume 2: Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma. Elsevier Academic Press: Burlington, MA, 2005, pp 267-275.
31. Quan SH. Anal cancers: squamous and melanoma. Cancer 1992;70:1384-1389.
32. Perry A, Aldape KD, George DH, et al. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004;101:2318-2326.
33. Alvarez G, Tan BR, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal. Mod Pathol 2005;18(Suppl 1):96A (Abstract).
34. Alvarez G, Perry A, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 2006;19(Suppl 1):101A (Abstract).
35. Le LH, Chetty R, Moore MJ. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol 2005;124:20-23.
36. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901.
37. al-Kasspooles M, Moore JH, Orringer MB, et al. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213-219.
38. Berger MS, Gullick WJ, Greenfield C, et al. Epidermal growth factor receptors in lung tumors. J Pathol 1987;152:297-307.
39. Kearsley JH, Leonard JH, Walsh MD, et al. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 1991;23:189-194.
40. Arteaga C. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7:31-39.
41. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96.
42. Gorgoulis V, Aninos D, Mikou P, et al. Expression of EGF, TGF-α and EGFR in squamous cell lung carcinomas. Anticancer Res 1992;12:1183-1187.
43. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-264.
44. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999;274:8865-8874.
45. Kopp R, Ruge M, Rothbauer E, et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 2002;22:1161-1167.
46. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-1346.
47. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997;89:341-343.